Release Date: 2022-03-15

Molecular Studies on Cognitive Disorders Associated with Cancer Treatment

Yesim Kaya (Author)

Release Date: 2022-03-15

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inA Handbook on Chemobrain with Molecular and Clinical Background
First Page47
Last Page52
DOIhttps://doi.org/10.69860/nobel.9786053358985.7
ISBN978-605-335-898-5 (PDF)
LanguageENG
Page Count6
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Yesim Kaya (Author)
Muğla Sıtkı Koçman University
https://orcid.org/0000-0002-2666-6383

  • Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007; 7: 192–201.

  • Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009; 9: 361–71.

  • Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients. Psychosom Med. 2001; 63: 376-86.

  • Cheung YT, Lim SR, Ho HK, et al. Cytokines as mediators of chemotherapy associated cognitive changes: current evidence, limitations, and directions for future research. PLoS One 2013; 8: e81234.

  • Cheung Y, Ng T, Shwe M, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study. Ann Oncol. 2015; 26: 1446-51.

  • Edwardson DW, Boudreau J, Mapletoft J, et al. Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PloS One 2017; 12: e0183662.

  • Janelsins MC, Kesler SR, Ahles TA, et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014; 26:102–13.

  • Ganz PA, Bower J, Kwan L, et al. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behavior Immun 2013; 30: S99-S108.

  • Gibbons PA. The lived experience of chemobrain in early-stage breast cancer in women 50 and under. J Alzheimers Neurodegener Dis. 2019; 5: 020.

  • Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013; 30 (suppl): S109-16.

  • Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000; 157: 683–94.

  • Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol. 2016; 37:11553-72.

  • Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013; 14: e218–28.

  • Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188-95.

  • Li Z, Zhao S, Zhang HL, et al. Proinflammatory factors mediate paclitaxel-induced Impairment of learning and memory. Mediators Inflam. 2018; 2018: 3941840.

  • Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol. 1999; 461: 75-8.

  • Nadin SB, Vargas-Roig LM, Drago G, et al. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. Cancer Lett. 2006; 239: 84-97.

  • Opal SM, Depalo VA. Anti-inflammatory cytokines. Chest. 2000; 117: 1162-72.

  • Person RT, Kronish K, Duan Z, et al. Cytokines IL-beta, IL-2, IL-6, IL-8, MCP-1,GM-CSF, and TNF-alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Oncol. 2000; 10: 33-41.

  • Povoski SP, Lipari AM, Agnese DM, et al. Inflammatory cytokines and comorbidity development in breast cancer survivors versus noncancer controls: Evidence for accelerated aging? J Clin Oncol. 2017; 35: 149.

  • Reers S, Pfannerstill A-C, Rades D, et al. Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer. Anticancer Res. 2013;33: 2481-9.

  • Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction:an international perspective from the Venice cognitive workshop.Ann Oncol. 2008; 19: 623–9.

  • Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008; 29: 1275–88.

  • Wang X-M, Walitt B, Saligan L, et al. Chemobrain: A critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy. Cytokine 2015; 72: 86-96.

  • Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of non-central nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 2015; 66:124-138.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!